@article{f76dddb5ea3444e7bbfde493063a2d04,
title = "Pharmacologic treatment for urgency-predominant urinary incontinence in women diagnosed using a simplified algorithm: A randomized trial",
abstract = "Objective: The purpose of this study was to evaluate clinical outcomes associated with the initiation of treatment for urgency-predominant incontinence in women diagnosed by a simple 3-item questionnaire. Study Design: We conducted a multicenter, double-blinded, 12-week randomized trial of pharmacologic therapy for urgency-predominant incontinence in ambulatory women diagnosed by the simple 3-item questionnaire. Participants (N = 645) were assigned randomly to fesoterodine therapy (4-8 mg daily) or placebo. Urinary incontinence was assessed with the use of voiding diaries; postvoid residual volume was measured after treatment. Results: After 12 weeks, women who had been assigned randomly to fesoterodine therapy reported 0.9 fewer urgency and 1.0 fewer total incontinence episodes/day, compared with placebo (P ≤.001). Four serious adverse events occurred in each group, none of which was related to treatment. No participant had postvoid residual volume of <250 mL after treatment. Conclusion: Among ambulatory women with urgency-predominant incontinence diagnosed with a simple 3-item questionnaire, pharmacologic therapy resulted in a moderate decrease in incontinence frequency without increasing significant urinary retention or serious adverse events, which provides support for a streamlined algorithm for diagnosis and treatment of female urgency-predominant incontinence.",
keywords = "antimuscarinic therapy, diagnostic algorithm, fesoterodine, urgency incontinence",
author = "Huang, {Alison J.} and Rachel Hess and Arya, {Lily A.} and Richter, {Holly E.} and Subak, {Leslee L.} and Bradley, {Catherine S.} and Rogers, {Rebecca G.} and Myers, {Deborah L.} and Johnson, {Karen C.} and Gregory, {W. Thomas} and Kraus, {Stephen R.} and Michael Schembri and Brown, {Jeanette S.}",
note = "Funding Information: Pfizer, Inc, provided funding for the study and the study medication but did not provide other input into the design of the study; collection, analysis, or interpretation of data; writing of the report; or the decision to submit the paper for publication. A.J.H. was additionally supported by grants RR024130 and 1K23AG038335-01A1 from the US National Institutes of Health ; however, the views expressed in this article do not necessarily represent those of the National Institutes of Health. A.J.H. and J.S.B. had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. No manuscript preparation assistance was provided by the study funders. Funding Information: A.J.H. has received a University of California San Francisco research grant from Pfizer, Inc , to conduct research related to urinary incontinence. L.A.A. has received a research grant from Pfizer, Inc . H.E.R. has received a research grant and participated in a speaker's bureau for Pfizer, Inc , received a research grant and participated in an advisory board for Astellas , and served as a consultant for Uromedica and GlaxoSmithKline. C.S.B. has served as a consultant for Astellas and for GlaxoSmithKline. S.R.K. has served as a consultant for Pfizer, Inc, and Allergan and has been a course director and teaching faculty member for Laborie. J.S.B. has received research grants related to incontinence through University of California San Francisco from Pfizer, Inc , and Mytrus, Inc . No other authors report any potential conflict of interest. ",
year = "2012",
month = may,
doi = "10.1016/j.ajog.2012.03.002",
language = "English (US)",
volume = "206",
pages = "444.e1--444.e11",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "5",
}